RJFSA
ADVM

Raymond James Financial Services Advisors’s Adverum Biotechnologies ADVM Stock Holding History

Raymond James Financial Services Advisors’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4,123
Closed -$407K – 3300
2021
Q1 		$407K Buy
4,123
+1,021
+33% +$123K ﹤0.01% 2425
2020
Q4 		$336K Buy
+3,102
New +$384K ﹤0.01% 2398
2020
Q3 		– Sell
-1,008
Closed -$210K – 2879
2020
Q2 		$210K Buy
+1,008
New +$179K ﹤0.01% 2459

Other funds holding ADVM

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
SFI
Sonic Fund II Honolulu, Hawaii $147M AUM 19.98% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Raymond James Financial Services Advisors's ADVM Position: Q2 2021 in Review

Raymond James Financial Services Advisors sold out of Adverum Biotechnologies (ADVM) in Q2 2021, closing a stake of 4,123 shares — an estimated $407K sold.

Raymond James Financial Services Advisors first reported a position in ADVM in Q2 2020 and held it in 3 quarters. The position peaked at $407K in Q1 2021. 118 funds tracked by Wall St. Rank hold ADVM as of Q2 2021.

  • Raymond James Financial Services Advisors reported no remaining Adverum Biotechnologies position as of Q2 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 4,123 Adverum Biotechnologies shares in Q2 2021, an estimated $407K.
  • Raymond James Financial Services Advisors first reported a position in Adverum Biotechnologies in Q2 2020 and held it in 3 quarters.
  • Raymond James Financial Services Advisors's Adverum Biotechnologies position peaked at $407K in Q1 2021.
  • 118 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.